New Phase 3b Data Reinforce the Safety and Efficacy Profile of Ruxolitinib Cream in Moderate AD
Ruxolitinib cream 1.5% (Opzelura, Incyte) significantly improves the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and is well-tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs), new research shows.